Compare JAZZ & OHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | OHI |
|---|---|---|
| Founded | 2003 | N/A |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 15.1B |
| IPO Year | 2007 | 2001 |
| Metric | JAZZ | OHI |
|---|---|---|
| Price | $246.11 | $46.88 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 11 |
| Target Price | ★ $217.57 | $46.55 |
| AVG Volume (30 Days) | 853.9K | ★ 1.5M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 5.74% |
| EPS Growth | N/A | ★ 25.16 |
| EPS | ★ 7.17 | 1.66 |
| Revenue | ★ $1,618,693,000.00 | $1,190,099,000.00 |
| Revenue This Year | $6.22 | $4.70 |
| Revenue Next Year | $7.68 | $5.38 |
| P/E Ratio | $33.66 | ★ $28.43 |
| Revenue Growth | N/A | ★ 13.19 |
| 52 Week Low | $123.89 | $39.26 |
| 52 Week High | $266.38 | $52.39 |
| Indicator | JAZZ | OHI |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 46.66 |
| Support Level | $237.05 | $46.49 |
| Resistance Level | $242.66 | $48.98 |
| Average True Range (ATR) | 7.29 | 0.84 |
| MACD | -1.25 | 0.14 |
| Stochastic Oscillator | 17.98 | 57.70 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Omega Healthcare Investors Inc is a real estate investment trust that invests in healthcare-related real estate properties located in the United States (U.S.), the United Kingdom (U.K.), and Canada. The company's objective is to provide attractive returns to investors while serving as the preferred capital partner to its third-party healthcare operating companies and affiliates, as well as other third-party healthcare operators, allowing them to focus on delivering a high level of care to their resident patients. Omega's investment portfolio mainly consists of skilled nursing facilities, assisted living facilities (ALFs), including care homes in the U.K., independent living facilities, rehabilitation and acute care facilities, and continuing care retirement communities.